MSI2 and cancer: ASOs targeting eIF4E, LIN28B, and Musashi-2 (MSI2) have shown robust anti-tumor activity in preclinical cancer models, particularly in leukemia and aggressive solid tumors, although challenges related to delivery, stability, and tissue specificity remain [215,216].